CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
我如何优化 CAR-T 细胞治疗后存在心脏和肺部并发症风险的患者
英文原题：How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy.
查看英文原题
How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞已改变血液系统恶性肿瘤患者的治疗方式。接受CAR-T 治疗的患者可能出现心血管和肺部并发症，这些并发症主要发生于细胞因子释放综合征背景下。此外，许多考虑接受CAR-T 治疗的患者原本就有心脏和肺部合并症。对于功能状态良好的患者，这些情况不应成为拒绝提供此类挽救生命疗法的理由。本文采用病例讨论的方式，介绍在CAR-T 治疗前如何评估并优化具有心脏和肺部风险因素患者的状况，以及如何管理治疗过程中可能出现的心肺并发症。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cells have transformed the care for patients with hematologic malignancies. Patients treated with CAR T cells may experience cardiovascular and pulmonary complications, which primarily occur in the setting of cytokine release syndrome.
In addition, many patients considered for CAR T-cell therapy have preexisting cardiac and pulmonary comorbidities. Among patients with good functional status, these conditions should not prevent patients from being offered these lifesaving therapies. In this article, we use a case-based approach to discuss how we evaluate and optimize conditions for patients with cardiac and pulmonary risk factors before CAR T-cell therapy and manage cardiac and pulmonary complications that may arise with treatment.
论文信息
- 作者
- Gutierrez C、Neilan TG、Grover NS
- 第一作者单位
- Department of Critical Care, The University of Texas MD Anderson Cancer Center, Houston, TX.United States
- 通讯作者单位
- Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.
- 文献类型
- 美国 NIH 资助研究 · 非美国政府资助研究
- 期刊
- Blood2023 May 18
- 原文标识
- PubMed 36827628 · DOI 10.1182/blood.2022017579
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →